Log in

LON:VER - Vernalis Share Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume819,492 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vernalis plc, a commercial stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Tuzistra XR for the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of amoxicillin antibiotic for the treatment of tonsillitis and pharyngitis secondary to streptococcus pyogenes in adults and pediatric patients; and frovatriptan for the acute treatment of migraine. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-118-9380000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive VER News and Ratings via Email

Sign-up to receive the latest news and ratings for VER and its competitors with MarketBeat's FREE daily newsletter.


Vernalis (LON:VER) Frequently Asked Questions

What is Vernalis' stock symbol?

Vernalis trades on the London Stock Exchange (LON) under the ticker symbol "VER."

How were Vernalis' earnings last quarter?

Vernalis plc (LON:VER) released its quarterly earnings results on Tuesday, September, 12th. The company reported ($4.10) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($4.50) by $0.40. The firm had revenue of $20.79 million for the quarter. View Vernalis' Earnings History.

Has Vernalis been receiving favorable news coverage?

News articles about VER stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vernalis earned a news impact score of 2.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the near term. View News Stories for Vernalis.

Who are some of Vernalis' key competitors?

What other stocks do shareholders of Vernalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vernalis investors own include Lloyds Banking Group (LLOY), Filtronic (FTC), GVC (GVC), Oxford BioMedica (OXB), Oxford Pharmascience Group (OXP), Roche Holding Ltd. Genussscheine (ROG), Bertrandt (BDT), BP (BP), Assura (AGR) and Firestone Diamonds (FDI).

Who are Vernalis' key executives?

Vernalis' management team includes the folowing people:
  • Mr. Ian R. Garland, CEO & Exec. Director (Age 52)
  • Mr. David MacKney, CFO & Exec. Director (Age 50)
  • Ms. Susan Wallcraft, Group Gen. Counsel & Company Sec.
  • Mr. Joseph Canny, VP of Marketing
  • Ms. Donna Radzik, Sr. VP of Pharmaceutical Quality Operations

How do I buy shares of Vernalis?

Shares of VER and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Vernalis' official website?

The official website for Vernalis is http://www.vernalis.com/.

How can I contact Vernalis?

Vernalis' mailing address is 100 Berkshire Place, Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom. The company can be reached via phone at +44-118-9380000.


MarketBeat Community Rating for Vernalis (LON VER)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  586
MarketBeat's community ratings are surveys of what our community members think about Vernalis and other stocks. Vote "Outperform" if you believe VER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel